CEACAM5 and non-small cell lung carcinoma: In a published open-label phase 1/2 study (NCT02187848), which included 92 heavily pretreated NSQ NSCLC patients with high (n = 64) or medium (n = 28) CEACAM5 expression, the most common TRAEs were corneal events (keratitis/corneal disorders).